Galectin-9 and T cell immunoglobulin mucin-3 pathway is a therapeutic target for type 1 diabetes

Endocrinology

Volumn 153, Issue 2, 2012, Pages 612-620

  Kanzaki, Motoko ^a   Wada, Jun ^a   Sugiyama, Koichi ^a   Nakatsuka, Atsuko ^a   Teshigawara, Sanae ^a   Murakami, Kazutoshi ^a   Inoue, Kentaro ^a   Terami, Takahiro ^a   Katayama, Akihiro ^a   Eguchi, Jun ^a   Akiba, Hisaya ^b   Yagita, Hideo ^b   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; GAMMA INTERFERON; MEMBRANE PROTEIN; MESSENGER RNA; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN CONTAINING PROTEIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELLS, CULTURED; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; FEMALE; GALECTINS; GENE EXPRESSION REGULATION; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED ICR; MICE, INBRED NOD; RECEPTORS, VIRUS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84856101211     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2011-1579     Document Type: Article

References (32)

1. Barondes SH, Cooper DN, Gitt MA, Leffler H 1994 Galectins. Structure and function of a large family of animal lectins. J Biol Chem 269:20807-20810
2. Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu F-T, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PWJ, Rini JM, Wang JL 1994 Galectins: a family of animal β-galactoside-binding lectins. Cell 76:597-598 (Pubitemid 24070645)
3. Wada J, Ota K, Kumar A, Wallner EI, Kanwar YS 1997 Developmental regulation, expression, and apoptotic potential of galectin-9, a β-galactoside binding lectin. J Clin Invest 99:2452-2461 (Pubitemid 27227724)
4. Wada J, Kanwar YS 1997 Identification and characterization of galectin-9, a novel β-galactoside-binding mammalian lectin. J Biol Chem 272:6078-6086 (Pubitemid 27102450)
5. Türeci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U 1997 Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin's disease. J Biol Chem 272:6416-6422 (Pubitemid 27118120)
6. Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M 1998 Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 273:16976-16984 (Pubitemid 28311730)
7. Yoshida H, Teraoka M, Nishi N, Nakakita S, Nakamura T, Hirashima M, Kamitori S 2010 X-ray structures of human galectin-9 C-terminal domain in complexes with a biantennary oligosaccharide and sialyllactose. J Biol Chem 285:36969-36976
8. Tsuchiyama Y, Wada J, Zhang H, Morita Y, Hiragushi K, Hida K, Shikata K, Yamamura M, Kanwar YS, Makino H 2000 Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Kidney Int 58:1941-1952
9. + alloreactive T cell and prolongs survival of skin graft. Cell Immunol 250:68-74
10. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK 2005 The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6:1245-1252 (Pubitemid 43045636)
11. Niwa H, Satoh T, Matsushima Y, Hosoya K, Saeki K, Niki T, Hirashima M, Yokozeki H 2009 Stable form of galectin-9, a Tim-3 ligand, inhibits contact hypersensitivity and psoriatic reactions: a potent therapeutic tool for Th1- and/or Th17-mediated skin inflammation. Clin Immunol 132:184-194
12. Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, Ito K, Takeshita K, Niki T, Saita N, Nishi N, Yamauchi A, Katoh S, Matsukawa A, Kuchroo V, Hirashima M 2008 Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 127:78-88
13. + regulatory T cells. Immunobiology 214:342-349
14. Arikawa T, Watanabe K, Seki M, Matsukawa A, Oomizu S, Sakata KM, Sakata A, Ueno M, Saita N, Niki T, Yamauchi A, Hirashima M2009 Galectin-9 ameliorates immune complex-induced arthritis by regulating FcγR expression on macrophages. Clin Immunol 133: 382-392
15. Seki M, Sakata KM, Oomizu S, Arikawa T, Sakata A, Ueno M, Nobumoto A, Niki T, Saita N, Ito K, Dai SY, Katoh S, Nishi N, Tsukano M, Ishikawa K, Yamauchi A, Kuchroo V, Hirashima M 2007 Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. Arthritis Rheum 56: 3968-3976 (Pubitemid 350262324)
16. Sakai K, Kawata E, Ashihara E, Nakagawa Y, Yamauchi A, Yao H, Nagao R, Tanaka R, Yokota A, Takeuchi M, Hirai H, Kimura S, Hirashima M, Yoshimura N, Maekawa T 2011 Galectin-9 ameliorates acute GVH disease through the induction of T-cell apoptosis. Eur J Immunol 41:67-75
17. Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai SY, Shinonaga R, Niki T, Nishi N, Tominaga A, Yamauchi A, Hirashima M 2007 Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 176: 27-35 (Pubitemid 47048051)
18. Sziksz E, Kozma GT, Pá llinger E, Komló si ZI, Adori C, Kovács L, Szebeni B, Rusai K, Losonczy G, Szabó A, Vannay A 2010 Galectin-9 in allergic airway inflammation and hyper-responsiveness in mice. Int Arch Allergy Immunol 151:308-317
19. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA 2007 Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 318:1141-1143 (Pubitemid 350134897)
20. + T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions. J Immunol 181:7660-7669
21. Dai SY, Nakagawa R, Itoh A, Murakami H, Kashio Y, Abe H, Katoh S, Kontani K, Kihara M, Zhang SL, Hata T, Nakamura T, Yamauchi A, Hirashima M 2005 Galectin-9 induces maturation of human monocyte-derived dendritic cells. J Immunol 175:2974-2981 (Pubitemid 41170515)
22. Li Y, Feng J, Geng S, Geng S, Wei H, Chen G, Li X, Wang L, Wang R, Peng H, Han G, Shen B, Li Y 2011 The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. Mol Immunol 48:670-677
23. Bluestone JA, Herold K, Eisenbarth G 2010 Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293-1300
24. Chou FC, Shieh SJ, Sytwu HK 2009 Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice. Eur J Immunol 39:2403-2411
25. Nakayama M, Akiba H, Takeda K, Kojima Y, Hashiguchi M, Azuma M, Yagita H, Okumura K 2009 Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation. Blood 113:3821-3830
26. Uchida Y, Ke B, Freitas MC, Yagita H, Akiba H, Busuttil RW, Najafian N, Kupiec-Weglinski JW 2010 T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology 139:2195-2206
27. + T cells in murine acute graft-versus-host disease. J Immunol 177:4281-4287
28. Sánchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng XX, Sabatos CA, Manlongat N, Bender O, Kamradt T, Kuchroo VK, Gutiérrez-Ramos JC, Coyle AJ, Strom TB 2003 Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 4:1093-1101 (Pubitemid 37428037)
29. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L 2005 Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352: 2598-2608 (Pubitemid 41007846)
30. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA 2002 Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346:1692-1698 (Pubitemid 34547482)
31. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, Gottlieb PA, Marks JB, McGee PF, Moran AM, Raskin P, Rodriguez H, Schatz DA, Wherrett D, Wilson DM, Lachin JM, Skyler JS 2009 Rituximab, B-lymphocyte depletion, and preservation of β-cell function. N Engl J Med 361:2143-2152
32. Strom TB, Koulmanda M 2008 Cytokine related therapies for autoimmune disease. Curr Opin Immunol 20:676-681